BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 17272321)

  • 1. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
    Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK
    Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer.
    Lee SS; Kim SB; Park SI; Kim YH; Ryu JS; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH
    Jpn J Clin Oncol; 2007 Nov; 37(11):829-35. PubMed ID: 17951334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of capecitabine plus cisplatin in patients with gastric cancer.
    Salah-Eldin MA; Ebrahim MA; AL-Ashry MS
    Anticancer Drugs; 2009 Mar; 20(3):191-6. PubMed ID: 19396018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.
    Polyzos A; Felekouras E; Karatzas T; Griniatsos J; Dimitroulis D; Polyzos K; Kontzoglou K; Mantas D; Karavokyros J; Nikiteas N; Tsavaris N; Syrigos K; Vafiadis I
    Anticancer Res; 2012 Sep; 32(9):4151-6. PubMed ID: 22993377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.
    Seol YM; Song MK; Choi YJ; Kim GH; Shin HJ; Song GA; Chung JS; Cho GJ
    Jpn J Clin Oncol; 2009 Jan; 39(1):43-8. PubMed ID: 18997184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study].
    Hu B; Yu JR; Wen ZZ; Shu YQ; Wang BC; Yin HR; Chen L; Bai YX; Liang J; Chen L; Cheng Y; Shen L; Zhou Y; Zhang HG; Li J; Wan DS; Chen S; Jia TZ; Jin ML
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):940-3. PubMed ID: 19173999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis.
    Jo JC; Lee JL; Ryu MH; Sym SJ; Lee SS; Chang HM; Kim TW; Lee JS; Kang YK
    Jpn J Clin Oncol; 2007 Dec; 37(12):936-41. PubMed ID: 18211985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma.
    Li YH; Wang FH; Jiang WQ; Xiang XJ; Deng YM; Hu GQ; Xu DM; Chen Y; Lin Q; He YJ
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):539-44. PubMed ID: 18172651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
    Hong YS; Lee J; Lee SC; Hwang IG; Choi SH; Heo JS; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):321-8. PubMed ID: 17143602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer.
    Cho EK; Lee WK; Im SA; Lee SN; Park SH; Bang SM; Park DK; Park YH; Shin DB; Lee JH
    Oncology; 2005; 68(4-6):333-40. PubMed ID: 16020960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer.
    Kos FT; Uncu D; Ozdemir N; Budakoglu B; Odabaş H; Abali H; Oksuzoglu B; Aksoy S; Zengin N
    Chemotherapy; 2011; 57(3):230-5. PubMed ID: 21597287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer.
    Kang YK; Ryu MH; Yoo C; Chang HM; Yook JH; Oh ST; Kim BS; Kim TW
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1435-43. PubMed ID: 20811894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
    Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
    Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer.
    Ocvirk J; Reberšek M; Skof E; Hlebanja Z; Boc M
    Am J Clin Oncol; 2012 Jun; 35(3):237-41. PubMed ID: 21399488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
    Lee J; Im YH; Cho EY; Hong YS; Lee HR; Kim HS; Kim MJ; Kim K; Kang WK; Park K; Shim YM
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):77-84. PubMed ID: 17762932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy.
    Peng PJ; Ou XQ; Chen ZB; Liao H; Peng YL; Wang SY; Zhang HY; Lin Z
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):323-8. PubMed ID: 23728706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
    Ohtsu A; Shah MA; Van Cutsem E; Rha SY; Sawaki A; Park SR; Lim HY; Yamada Y; Wu J; Langer B; Starnawski M; Kang YK
    J Clin Oncol; 2011 Oct; 29(30):3968-76. PubMed ID: 21844504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
    Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer.
    Chua DT; Yiu HH; Seetalarom K; Ng AW; Kurnianda J; Shotelersuk K; Krishnan G; Hong RL; Yang MH; Wang CH; Sze WK; Ng WT
    Head Neck; 2012 Sep; 34(9):1225-30. PubMed ID: 22076785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.